Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Sunpharma Ltd — Q4 FY25
Sun Pharma reported Q4 FY25 consolidated revenue of INR 12,816 crore, up 8.5% YoY, with EBITDA of INR 3,716 crore (+22.4% YoY) and margin expansion of 340 bps to 28.7%.
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Sun Pharma reported Q4 FY25 consolidated revenue of INR 12,816 crore, up 8.5% YoY, with EBITDA of INR 3,716 crore (+22.4% YoY) and margin expansion of 340 bps to 28.7%. India formulation sales grew 13.6% YoY, while US sales declined 2.5% due to generic erosion. Global specialty sales grew 8.6%, led by ILUMYA (+17% full year). Management guided for mid-to-high single-digit revenue growth in FY26, with an additional $100 million investment in new specialty product launches. R&D spend is expected at 6%-8% of sales. Key risks include US generic pricing pressure, uncertainty around MFN/tariff policies, and potential delays in Leqselvi launch due to ongoing patent litigation.
सन फार्मा ने वित्त वर्ष 2025 की चौथी तिमाही में कुल कमाई 12,816 करोड़ रुपये दर्ज की, जो पिछले साल से 8.5% अधिक है। कंपनी का परिचालन लाभ (EBITDA) 3,716 करोड़ रुपये रहा, जो 22.4% बढ़ा। मुनाफा मार्जिन 28.7% हो गया, जो पहले से 3.4% अधिक है। भारत में दवा बिक्री 13.6% बढ़ी, लेकिन अमेरिका में सस्ती जेनेरिक दवाओं के दबाव से बिक्री 2.5% घटी। वैश्विक स्पेशलिटी दवाओं की बिक्री 8.6% बढ़ी, खासकर ILUMYA से। कंपनी ने अगले वित्त वर्ष में 5-9% कमाई बढ़ोतरी का अनुमान जताया है और नई स्पेशलिटी दवाओं के लिए 100 मिलियन डॉलर निवेश करेगी। रिसर्च पर खर्च बिक्री का 6-8% रहेगा। मुख्य जोखिम हैं: अमेरिका में जेनेरिक दवाओं की कीमत दबाव, टैरिफ नीतियों में बदलाव, और Leqselvi दवा के लॉन्च में पेटेंट विवाद के कारण देरी।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
US generic pricing pressure
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India formulation sales growth
13.6%
+13.6% YoY
India formulation sales grew 13.6% YoY to INR 42,130 million in Q4 FY25.
Global specialty sales growth
8.6%
+8.6% YoY
Global specialty sales grew 8.6% YoY to $295 million in Q4 FY25.
ILUMYA full-year sales
$681M
+17% YoY
ILUMYA full-year FY25 sales grew 17% to $681 million.
India market share
8.3%
+30bps YoY
Sun Pharma's India market share increased to 8.3% from 8.0% a year ago.
What Changed vs Last Quarter
NEW
FY26 revenue growth: mid-to-high single digit
Management expects consolidated top-line growth of mid-to-high single digits for FY2026.
NEW
Additional $100M investment in specialty launches
Approximately $100 million additional spend in FY26 for commercialization of new specialty products.
NEW
R&D spend guidance: 6%-8% of sales
FY2026 R&D spend expected to be 6%-8% of sales.
NEW
Leqselvi launch in Q2 FY26
Leqselvi to be launched in the US in the second quarter of FY2026.
DROPPED
FY25 R&D spend to be less than 7% of sales
Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales.
DROPPED
Leqselvi launch timeline dependent on litigation outcome
Oral arguments for Leqselvi patent litigation expected in April 2025; if favorable, launch could occur before patent expiry in December 2026.
DROPPED
Specialty sales growth to normalize after Q3 inventory build
Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.
NEW RISK
US generic pricing pressure
US generics declined due to additional competition and pricing pressure, which may continue.
NEW RISK
Tax rate increase
Effective tax rate rose to 19.8% in Q4 from 5.1% last year, expected to inch up further.
RISK GONE
FDA Compliance at Halol Facility
Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.
RISK GONE
Clinical Trial Delays Impacting R&D Pipeline
Delays in finalizing protocols and starting clinical trials have led to lower R&D spend and may push back pipeline milestones.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Management aims to grow India formulation business faster than the Indian pharmaceutical market on an annualized basis.
Mentioned in Q1 FY24, Q3 FY24
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
Fast read
Guidance and risk preview
Management expects consolidated top-line growth of mid-to-high single digits for FY2026.
US generics declined due to additional competition and pricing pressure, which may continue.
View Risks →